Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orgenesis ( (ORGS) ) has shared an announcement.
On July 29, 2025, Orgenesis Inc. was notified by the OTC Markets Group that its common stock would be moved from the Pink Limited to the Expert Market tier. This decision was due to Orgenesis being over 180 days late in filing its 10-K for the period ending December 31, 2024, thus failing to comply with SEC Rule 15c2-11. The company was unable to address this issue within the given 15-day cure period.
Spark’s Take on ORGS Stock
According to Spark, TipRanks’ AI Analyst, ORGS is a Underperform.
Orgenesis faces substantial financial challenges, with negative revenue and cash flow issues indicating significant instability. Despite negative technical indicators, recent corporate governance improvements may provide a slight strategic advantage. However, these factors are overshadowed by the company’s overarching financial distress, resulting in a low overall stock score.
To see Spark’s full report on ORGS stock, click here.
More about Orgenesis
Average Trading Volume: 4,153
Technical Sentiment Signal: Sell
Current Market Cap: $113.7K
For a thorough assessment of ORGS stock, go to TipRanks’ Stock Analysis page.